Catalyst Event
Biogen Inc (BIIB) · Other
From KEDI Palantir Fixed Tech100 Index (KPLTT100)
5/24/2026, 12:00:00 AM
U.S. FDA PDUFA action date for the subcutaneous formulation of LEQEMBI for treatment initiation in early Alzheimer's disease is scheduled. This regulatory milestone is estimated to have a medium impact on stock price.
Korean Translation
미국 FDA의 초기 알츠하이머병 치료를 위한 레켐비(LEQEMBI) 피하주사 제형의 처방의약품 신청자 수수료법(PDUFA) 목표일이 예정됨. 해당 규제 마일스톤은 주가에 중간 정도의 영향을 미칠 것으로 예상됨.
Related Recent Events
Broadcom Inc (AVGO) · Earnings Release
Q2 2026 earnings release on June 4, 2026; a Medium impact is estimated as quarterly earnings are key drivers of stock volatility, scheduled.
6/4/2026, 12:00:00 AM
Credo Technology Group Holding Ltd (CRDO) · Earnings Release
Next earnings release for Q4 fiscal 2026 on June 1, 2026, scheduled.
6/1/2026, 12:00:00 AM
Biogen Inc (BIIB) · Earnings Release
Biogen's Q1 2026 earnings release is expected around this date, based on past reporting schedules. Earnings releases typically result in moderate price volatility.
5/7/2026, 12:00:00 AM
Natera Inc (NTRA) · Earnings Release
Natera is expected to report its Q1 2026 earnings on May 7, 2026, with analysts forecasting an EPS of approximately -$0.55. Market impact is estimated at ≥1% as earnings dates are routine; scheduled.
5/7/2026, 12:00:00 AM
AppLovin Corporation (APP) · Earnings Release
AppLovin's Q1 2026 earnings release is scheduled.
5/6/2026, 12:00:00 AM
Microchip Technology Inc (MCHP) · Earnings Release
Q4 Fiscal Year 2026 earnings release including guidance for net sales of $1.26 billion +/- $20 million and non-GAAP diluted EPS of $0.48–$0.52. Low importance estimated as guidance is within expected ranges scheduled.
5/6/2026, 12:00:00 AM